Treatment outcome comparisons of first‐line targeted therapy in patients with KRAS wild‐type metastatic colorectal cancer: A nationwide database study
Abstract Background The first‐line systemic therapy for metastatic colorectal cancer (mCRC) is a combination of one targeted therapy agent and a chemotherapy doublet. Whether bevacizumab or anti‐epidermal growth factor receptor (anti‐EGFR) monoclonal antibody (mAb) is the more effective addition to...
Main Authors: | Yi‐Hsin Liang, Kuo‐Hsing Chen, Yu‐Yun Shao |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-07-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.6196 |
Similar Items
-
The Place of Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer
by: Alexios Matikas, et al.
Published: (2015-03-01) -
STUDY DATA OF KRAS- AND RAS-UNMUTATED (WILD) TYPE OF COLORECTAL CANCER
by: V. A. Gorbunova
Published: (2015-05-01) -
An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer
by: Gerardo Rosati, et al.
Published: (2022-11-01) -
METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY
by: N. A. Avxentyev, et al.
Published: (2016-09-01) -
Optimal solutions in the third line therapy for refractory metastatic colorectal cancer. CORRECTness and CONCURency
by: R. T. Ayupov, et al.
Published: (2021-12-01)